5. Morrissey et al. Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy. Cardiovasc J Afr. 2011;22:38–44;
6. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9-16.
7. Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB, et al. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart 2011;97(23):1957-60.
8. Hagege AA, Caudron E, Damy T, et al. Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study. Heart. 2011;97:131-136.
9. Terryn W, Deschoenmakere G, De Keyser J, Meersseman W, Van Biesen W, Wuyts B, et al. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int J Cardiol 2013;167(6):2555-60.
10. Palecek T, Honzikova J, Poupetova H, Vlaskova H, Kuchynka P, Golan L, et al. Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). J Inherit Metab Dis 2014;37(3):455-60.
11. Vieitez I, Souto-Rodriguez O, Fernandez-Mosquera L, et al. Fabry disease in the Spanish population: observational study with detection of 77 patients. Orphanet J Rare Dis. 2018 Apr 10;13(1):52.
12. Maron MS, Xin W, Sims KB, Butler R, Haas TS et al. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018 Feb;131(2):200.e1-200.e8.
13. Ommen SR, NishimuraRA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart 2003;89:929–30.
14. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, Journal of the American Society of Echocardiography January 2015
15. Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89:44-54.
16. Mehta et al. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey J Med Genet. 2009;46:548–52;
17. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. J Am Med Assoc 1999; 281:249–54.
18. Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment. Orphanet J Rare Dis. 2015 Sep 29;10:125. doi: 10.1186/s13023-015-0338-2.
19. Schiffman R, Kopp JB, Austin 3rd HA, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743–9.

Uncorrected Proof

Table 1 Clinical characteristics of study patients.

	HCM (n=80)
Male / Female, n (%)	53 (66%) / 27 (34%)
Age	41.5 ± 12.7
Ejection fraction (%)	60.7 ± 7.4
Interventricular septal wall thickness (mm)	18.2 ± 4.4
Posterior wall thickness (mm)	13.5 ± 2.1
LV end-diastolic diameter (mm)	47.4 ± 6.2
LV end-systolic diameter (mm)	27.8 ± 6.5
Left atrial diameter (mm)	36.7 ± 8.5
Systolic pulmonary artery pressure (mmHg)	34.5 ± 9.8
LV mass index (LVMI)(g/m²)	171.05 ± 48.5

Data are shown as mean ± SD (range). HCM, hypertrophic cardiomyopathy; LV, left ventricular.

Uncorrected Proof

Table 2 Clinical characteristics and genetic results in patients with Fabry disease.

	Patient 1	**Patient 2**
Plasma a-Gal A activity (μmol/L/h) *	0.5 μmol/L/h	0.4 μmol/L/h
Lyso-Gb3 (ng/mL) #	7.8	5.10
Gender	Male	Male
Age (years)	49	38
Pattern of LVH	Concentric	Concentric
Interventricular wall thickness (mm)	18	20
Posterior wall thickness (mm)	18	20
LV end-diastolic diameter (mm)	52	54
LV end-systolic diameter (mm)	37	42
Ejection fraction (%)	60	44
LV mass index	241	278
Acroparesthesia	+	+
Angiokeratoma	-	-
Hypohydrosis	-	-
Corneal opacities	-	-
Proteinuria	+	+
Cerebral infarction	-	-
Mutations - Missense	p.R112C	p.R301Q
Nucleotide change	c.334C>T	c.902>A

*Reference value ≥3.3 μmol/L/hour. #Reference value ≤1.8ng/mL.

Uncorrected Proof



Figure 1. Prevalence of Fabry disease in various populations with hypertrophic cardiomyopathy patients

Uncorrected Proof



Figure 2.



Figure 3.

Uncorrected Proof